Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2021

View Archived Issues

KAT7 identified as a driver of cellular senescence

MediciNova initiates phase II trial of ibudilast in COVID-19 patients at risk of ARDS

First-in-human study evaluates EMB-02 for advanced solid tumors

In situ-gelling hydrogel with tunable properties for intranasal drug delivery to the brain

Hyper-IL-6 gene therapy stimulates axon regeneration and functional recovery after SCI in mice

Antibody-drug conjugates with new PNU-159682 derivatives show anticancer efficacy in vivo

Orladeyo approved in Japan for the prophylactic treatment of hereditary angioedema

Qilu Regor Therapeutics patents MALT1 inhibitors

Lundbeck discloses new antidepressants

Galecto Biotech identifies new LGALS1 and/or LGALS3 inhibitors

BeiGene presents new MAP4K1 inhibitors

New IL-10 variant proteins presented by Korean investigators

Funding supports Vaxess' work on mRNA-based single-dose, refrigeration-free vaccine patch

Elasmogen identifies novel anti-COVID-19 therapeutic candidates

Molecularly, skin disease shares much with development

FDA approves Lupkynis oral therapy for lupus nephritis

Hunterase ICV approved in Japan for MPS II

BirchBioMed reports phase II data on FS-2 for keloid scars

Novel GLP-1 and FGF-21 dual agonist D-1 shows potential for diabetes and NASH

Japanese approval for Yescarta for relapsed or refractory DLBCL

Antengene receives Chinese clearance for phase II/III study of selinexor for DLBCL

Phase III studies of faricimab in wet AMD meet primary endpoint

FDA approves Cabometyx plus Opdivo for advanced RCC

Neuregulin-1 beta 1 linked to early phase multiple sclerosis pathogenesis

Zydus reports phase IIb data on desidustat in patients with COVID-19

COLCORONA trial shows colchicine reduces risk of COVID-19-related complications

Japanese approval of Calquence for relapsed or refractory CLL